Why Harmony Biosciences Stock Got Mashed on Monday

HRMY dropped more than 5% on Monday after Harmony Biosciences announced a planned CEO succession. COO Peter Anastasiou will take over from CEO Jeffrey Dayno effective January 1, 2027, in what the company framed as a planned transition.

The leadership news landed alongside reassurance on the fundamentals. Harmony says its strategic priorities remain unchanged, and it reiterated full-year Wakix revenue guidance of $1-$1.04 billion. Despite that, investors sold the stock on the announcement.

Interpretation: the selloff looks like a reaction to the change at the top rather than to any change in the business outlook. Unchanged guidance and a named internal successor, rather than an outside search, argue the company is signaling continuity. Anastasiou's current role as COO means he is already inside the operating structure, which may limit execution risk. That is our read of the evidence, not a stated company claim.

The Motley Fool analyst covering the move suggested the decline may offer a buying opportunity at a discount.